Two Companies Combine Retinal Imaging and Blood Biomarkers for Earlier Alzheimer's Detection
Circular Genomics and Vitazi.ai announced a partnership to develop a two-step diagnostic workflow for early Alzheimer's disease detection. The collaboration pairs Vitazi.ai's AI-powered retinal imaging analysis with Circular Genomics' circular RNA biomarkers in blood samples.
The workflow starts with non-invasive retinal imaging in primary care or optometry settings to identify patients at elevated risk. A second step uses blood tests to detect brain-derived circular RNA markers, confirming early disease biology with molecular precision.
Why This Matters for Development Teams
The partnership centers on building multimodal machine learning models-the kind of data analysis work that requires integrating disparate data sources. Developers will need to handle retinal imaging data alongside molecular biomarker profiles in unified predictive systems.
Circular RNA biomarkers offer a different signal than traditional protein-based tests. They're more stable, enriched in brain tissue, and provide pathway-level disease insight rather than single-point measurements. This complexity demands more sophisticated machine learning approaches to extract clinical value from combined data modalities.
The Clinical Problem
Alzheimer's disease is typically diagnosed years after symptom onset. Early-stage patients often go undetected because existing diagnostic tools lack accuracy, accessibility, or cost-effectiveness at scale.
A two-step triage system could address this gap. Retinal imaging provides a broad screening mechanism with minimal infrastructure requirements. Blood biomarkers then confirm findings with molecular detail, reducing false positives and supporting pharmaceutical companies in clinical trial enrollment and patient stratification.
Technical Architecture
The system treats the retina as a window into neurological health. Vitazi.ai's platform extracts structural and vascular patterns from retinal images using AI. Circular Genomics contributes molecular data from blood samples.
The challenge lies in fusing these orthogonal signals-structural imaging and molecular markers-into single predictive models. This requires careful feature engineering, data normalization, and validation across diverse patient populations.
Paul Sargeant, CEO of Circular Genomics, said the partnership extends the company's platform reach across primary care and specialty settings. Jeremy Stueven, CEO of Vitazi.ai, described the approach as combining "complementary data modalities that reflect different dimensions of human biology."
Broader Applications
Both executives framed this as a template for multimodal disease detection beyond Alzheimer's. Nikolaos Mellios, chief scientific officer at Circular Genomics, said the work "represents a fundamental advancement in how we model and measure neurodegenerative disease biology, with implications that extend well beyond Alzheimer's to the broader landscape of precision neurology."
For healthcare systems and pharmaceutical partners, the value lies in earlier intervention windows. Disease-modifying therapies for Alzheimer's work best when administered early. A scalable screening method could shift detection upstream, where treatment has greater clinical and economic impact.
Your membership also unlocks:
